What is Kymera Therapeutics's stock issuance proceeds?

Kymera Therapeutics (KYMR) reported stock issuance proceeds of $19.19M in Q1 2026.

What is the long-term trend for Kymera Therapeutics's stock issuance proceeds?

Over 3 years (2021 to 2025), Kymera Therapeutics's stock issuance proceeds has grown at a -100.0% compound annual growth rate (CAGR), from $7.63M to $0.

What does stock issuance proceeds mean?

Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.

Kymera Therapeutics KYMR Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

Regeneron PharmaceuticalsREGN

$163.1M+169%

ImmunityBio, Inc.IBRX

$971K+341%

Krystal Biotech, Inc.KRYS

$6.5M+345%

Spyre Therapeutics, Inc.SYRE

$2.68M+1,128%

Protagonist TherapeuticsPTGX

——

Immunovant, Inc.IMVT

——

Other financials

Income statement

See full

Revenue$34.4M+55.5%

Operating income-$84.2M-13.1%

Net income-$69.2M-5.6%

EPS (diluted)-$0.71+13.4%

Balance sheet

See full

Cash & equivalents$144.1M+60.2%

Total debt$82.2M-6.5%

Total equity$1.5B+95.8%

Total assets$1.7B+81.7%

Cash flow

See full

Operating cash flow-$88.8M-12.2%

CapEx$434.0K-7.1%

Free cash flow-$89.3M-12.1%

Valuation

See full

Market cap$7.44B+283%

Enterprise value$7.38B+280%

P/S144.5×+111×

Profitability

See full

Operating margin-697.7%+635pp

Net margin-612%+602pp

FCF margin-474%+92.4pp

Returns & leverage

See full

Return on equity-27.1%-3.7pp

Debt / equity0.1×-0.1×

Current ratio10.8×+2.3×

Where this comes from

Reported directly by Kymera Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromStockPlans.

The official record: Kymera Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kymera Therapeutics's stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Kymera Therapeutics's stock issuance proceeds?: Kymera Therapeutics (KYMR) reported stock issuance proceeds of $19.19M in Q1 2026.
What is the long-term trend for Kymera Therapeutics's stock issuance proceeds?: Over 3 years (2021 to 2025), Kymera Therapeutics's stock issuance proceeds has grown at a -100.0% compound annual growth rate (CAGR), from $7.63M to $0.
What does stock issuance proceeds mean?: Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.